Can surgery prolong survival in stage 4 skin cancer, malignant melanoma?

Surgical Oncology of North America journal, according to a study published there, reports that surgery can significantly prolong life in malignant melanoma that has spread to abdominal organs.
As is known, malignant melanoma is among the most aggressively progressing cancer types. Stage 4 disease in particular substantially shortens these patients' survival. Nevertheless, treatment research over the last 5 years has markedly prolonged survival in malignant melanoma. Advances in both immunotherapy and targeted therapies have led us oncologists to perceive stage 4 (metastatic) malignant melanoma as a manageable disease.
Malignant melanoma is a cancer located in the skin. In stage 4, if the disease has spread to other organs, surgery is usually not preferred. Because of the biology of the disease, surgery is believed not to prolong life if spread to distant organs (metastasis) is present.
However, the Surgical Oncology of North America journalpublished study results that impressed us all. They demonstrated that, when malignant melanoma, a type of skin cancer, spreads to abdominal organs, surgery in appropriately selected patients can significantly prolong life in addition to today's developing treatments (immunotherapy and targeted therapies).
The studyenrolled a total of 1623 patients. Nearly 305 had multiple metastases; the others had metastases to organs such as the digestive system, spleen, adrenal glands and pancreas. Among 1623 patients, 392 underwent surgery on metastatic sites, or surgery combined with cryoablation (destroying the tumor by freezing) or radiofrequency ablation (destroying it by burning).
At the end of the research, survival was found to be 18 months in malignant melanoma patients with abdominal spread who underwent surgery, compared with 7 months in those who did not. This showed that surgery in such situations creates a substantial survival difference. Naturally, a survival advantage from surgery in patients without highly aggressive metastases is predictable. Whatever the circumstances, however, such a survival difference is important to us.
In summary, if malignant melanoma with abdominal spread does not show aggressive metastasis, meaning the cancer does not affect multiple organs simultaneously, or if involvement of multiple organs is countable and not highly aggressive, surgery alone may be used. In selected patients, surgery can also be combined with local ablative treatments such as cryoablation and radiofrequency ablation. These approaches suggest an additional benefit alongside today's immunotherapies and targeted therapies.
This study therefore provides extremely important information for both our patients and the oncologists managing the disease. However, referring all patients for surgery or offering surgery to patients with multiple metastases on the basis of this study would be inappropriate. It is extremely important that these patients' treatment be managed through decisions by tumor boards involving multiple physicians.
Sources
Metastasectomy for stage IV melanoma.
Surg Oncol Clin N Am. 2015 Apr;24(2):279-98. doi: 10.1016/j.soc.2014.12.006.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.